texture_fondlogo
Nov 10

Research Success Story

Posted by maciviva

Thanks to a Horizon 2020 grant, 6 biotech companies are pool- ing their expertise to develop solid-form, thermostable vaccines that will be cheaper, safer and needle-free. Bern, Switzerland – September 2016 — The funding turned out to be only one of the advantages of the MACIVIVA project, says its Scientific Co- ordinator, Dr Sylvain Fleury,…

Read More

texture_fondlogo
May 29

Chimera, Maciviva Press release

Posted by maciviva

Chimera Biotec Awarded Grant to Support Ultra Sensitive Efficacy Testing of an Oral and Nasal Vaccine Delivery Platform. Dortmund, Germany – 29th May, 2015 — Chimera Biotec GmbH, a specialist in ultra sensitive immunoassay development has received a significant project grant as part of a consortium looking to establish cold-chain independent virosome-based vaccine…

Read More

texture_fondlogo
May 18

Upperton, Maciviva Press release

Posted by maciviva

Upperton Awarded Grant to Create Oral and Nasal Vaccine Delivery Platform. Nottingham, UK – 18th May, 2015 — Upperton Ltd, a specialist spray drying and drug formulation company today announced that it has received a significant project grant as part of a consortium looking to evaluate, develop and manufacture thermo stable and cold-chain…

Read More

texture_fondlogo
Apr 20

Catalent, Maciviva Press release

Posted by maciviva

Catalent awarded grant as part of vaccine research consortium. Somerset, N.J. – April 20, 2015 — Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has received a significant project grant as part of a consortium looking to evaluate,…

Read More

texture_fondlogo
Apr 20

Mymetics, Maciviva Press release

Posted by maciviva

Mymetics-led consortium awarded € 8.4 million for development of thermo stable and cold-chain independent vaccines. – Mymetics virosome vaccine technology and HIV vaccine candidate to be used as basis to develop a scalable manufacturing process within 3.5 years.   – Funding this project can represent a major innovation in the world of vaccine…

Read More